Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Jan 6;17:35–40. doi: 10.2147/CCID.S446369

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2024 Chen et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Patient (A) ulcerative lesions with massive purulent discharges in perianal area before abrocitinib treatment (Aa); extensive infiltration of lymphocytes and neutrophils and necrotising vasculitis (Ab, ×100); significant improvement of skin lesions 1 week after abrocitinib and cyclosporine A treatment (Ac) and 4 weeks after starting abrocitinib treatment (Ad). Patient (B) multiple ulcers and tan necrosis near both ankle joints (Ba, b); cellulose like degeneration of capillary wall, and vascular thrombosis and inflammation (Bc, ×100); markedly improvement of skin lesions 1 week (Bd, e) and 6 weeks (Bf, g) after abrocitinib treatment. Patient (C) nodules and abscesses of the axillary (Ca, b); hyperplasia of the hair follicle infundibulum epithelium and infiltration of lymphocyte (Cc, ×40); improvement of skin lesions 2 weeks after abrocitinib and doxycycline treatment (Cd, e) and 6 weeks after starting abrocitinib treatment (Cf, g).